200,000+ products from a single source!
sales@angenechem.com
Home > Other Heterocycles > 124620-88-8
124620-88-8 | Spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], 2'-methyl-
CAS No: 124620-88-8 Catalog No: AG000MH4 MDL No:MFCD24395706
Product Description
Catalog Number:
AG000MH4
Chemical Name:
Spiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane], 2'-methyl-
CAS Number:
124620-88-8
Molecular Formula:
C10H17NOS
Molecular Weight:
199.3131
MDL Number:
MFCD24395706
IUPAC Name:
2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
InChI:
InChI=1S/C10H17NOS/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11/h8-9H,2-7H2,1H3
InChI Key:
WUTYZMFRCNBCHQ-UHFFFAOYSA-N
SMILES:
CC1SCC2(O1)CN1CCC2CC1
EC Number:
946-023-8
Properties
Complexity:
215
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
199.103g/mol
Formal Charge:
0
Heavy Atom Count:
13
Hydrogen Bond Acceptor Count:
3
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
199.312g/mol
Monoisotopic Mass:
199.103g/mol
Rotatable Bond Count:
0
Topological Polar Surface Area:
37.8A^2
Undefined Atom Stereocenter Count:
2
Undefined Bond Stereocenter Count:
0
XLogP3:
1.5
Literature
| Title | Journal |
|---|---|
| Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia. | Head & neck 20120801 |
| Distinct effects of cevimeline and pilocarpine on salivary mechanisms, cardiovascular response and thirst sensation in rats. | Archives of oral biology 20120401 |
| Treatment of Sjögren's syndrome-associated dry eye an evidence-based review. | Ophthalmology 20110701 |
| Abnormal subcellular localization of AQP5 and downregulated AQP5 protein in parotid glands of streptozotocin-induced diabetic rats. | Biochimica et biophysica acta 20110501 |
| Cevimeline-induced monophasic salivation from the mouse submandibular gland: decreased Na+ content in saliva results from specific and early activation of Na+/H+ exchange. | The Journal of pharmacology and experimental therapeutics 20110401 |
| Cevimeline (Evoxac ®) overdose. | Journal of medical toxicology : official journal of the American College of Medical Toxicology 20110301 |
| New epitopes and function of anti-M3 muscarinic acetylcholine receptor antibodies in patients with Sjögren's syndrome. | Clinical and experimental immunology 20101001 |
| The relationship between the drug concentration profiles in plasma and the drug doses in the colon. | Chemical & pharmaceutical bulletin 20101001 |
| Dosage form design and in vitro/in vivo evaluation of cevimeline extended-release tablet formulations. | International journal of pharmaceutics 20100104 |
| Comparison of the effects of pilocarpine and cevimeline on salivary flow. | International journal of dental hygiene 20090501 |
| Identification of aquaporin-5 and lipid rafts in human resting saliva and their release into cevimeline-stimulated saliva. | Biochimica et biophysica acta 20090101 |
| Sjögren's syndrome patients presenting with hypergammaglobulinemia are relatively unresponsive to cevimeline treatment. | Modern rheumatology 20090101 |
| Cevimeline enhances the excitability of rat superior salivatory neurons. | The journal of medical investigation : JMI 20090101 |
| Correlation between salivary secretion and salivary AQP5 levels in health and disease. | The journal of medical investigation : JMI 20090101 |
| Effects of pilocarpine and cevimeline on Ca2+ mobilization in rat parotid acini and ducts. | The journal of medical investigation : JMI 20090101 |
| Effects of cevimeline on the immunolocalization of aquaporin-5 and the ultrastructure of salivary glands in Sjögren's syndrome model mice. | The Kurume medical journal 20090101 |
| Parotid irrigation and cevimeline gargle for treatment of xerostomia in Sjögren's syndrome. | The Journal of rheumatology 20081101 |
| Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor agonist. | American journal of physiology. Gastrointestinal and liver physiology 20080701 |
| The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren's syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study. | Clinical rheumatology 20080401 |
| Cevimeline. | Drugs 20080101 |
| Open-label, long-term safety study of cevimeline in the treatment of postirradiation xerostomia. | International journal of radiation oncology, biology, physics 20071201 |
| Xerostomia: causes and treatment. | The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20071201 |
| Effect of a muscarinic M3 receptor agonist on gastric motility. | Journal of gastroenterology and hepatology 20071101 |
| Efficacy prediction of cevimeline in patients with Sjögren's syndrome. | Clinical rheumatology 20070801 |
| Cevimeline for the treatment of postirradiation xerostomia in patients with head and neck cancer. | International journal of radiation oncology, biology, physics 20070715 |
| Effect of cevimeline on radiation-induced salivary gland dysfunction and AQP5 in submandibular gland in mice. | The Bulletin of Tokyo Dental College 20070501 |
| Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations. | Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 20070301 |
| [Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Recommendations for supportive therapy for Sjögren's syndrome]. | Zeitschrift fur Rheumatologie 20070201 |
| Effects of cevimeline on salivation and thirst in conscious rats. | Archives of oral biology 20070101 |
| Unraveling the mysteries of saliva: its importance in maintaining oral health. Transcript of a lecture presented on August 6 at the 2006 AGD Annual Meeting & Exposition. | General dentistry 20070101 |
| The therapy of Sjogren's syndrome: a review. | La Clinica terapeutica 20070101 |
| Cevimeline reduced mouth dryness and increased salivary flow in patients with xerostomia complicating chronic graft-versus-host disease. | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 20060701 |
| New approaches to preventing xerostomia. | The journal of supportive oncology 20060201 |
| Cevimeline hydrochloride improved cholinergic dysfunction in a patient with pure autonomic failure. | Journal of neurology 20060101 |
| Assessment of the use of sialogogues in the clinical management of patients with xerostomia. | Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry 20060101 |
| Management of xerostomia related to radiotherapy for head and neck cancer. | Oncology (Williston Park, N.Y.) 20051201 |
| Identification of AQP5 in lipid rafts and its translocation to apical membranes by activation of M3 mAChRs in interlobular ducts of rat parotid gland. | American journal of physiology. Cell physiology 20051101 |
| Idiopathic CD4+ lymphocytopenia and Sjogren syndrome. | Archives of ophthalmology (Chicago, Ill. : 1960) 20050701 |
| Effect of cevimeline on salivary components in patients with Sjögren syndrome. | Pharmacology 20050501 |
| Salivary hypofunction and xerostomia: diagnosis and treatment. | Dental clinics of North America 20050401 |
| Dentistry. Implications and management of xerostomia in the HIV patient. | HIV clinician 20050101 |
| Dentistry. Clinic assesses effect of medication on dry mouth syndrome. | HIV clinician 20050101 |
| Xerostomia secondary to Sjögren's syndrome in the elderly: recognition and management. | Drugs & aging 20050101 |
| [Clinical significance of cevimeline hydrochloride in the treatment of dry mouth in patients with Sjögren's syndrome]. | Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology 20041001 |
| Therapeutic effect of cevimeline on dry eye in patients with Sjögren's syndrome: a randomized, double-blind clinical study. | American journal of ophthalmology 20040701 |
| [Future therapy strategies for salivary gland impairment]. | Refu'at ha-peh veha-shinayim (1993) 20040701 |
| Cevimeline gargle for the treatment of xerostomia in patients with Sjögren's syndrome. | Annals of the rheumatic diseases 20040601 |
| [The effectiveness of cevimeline hydrochloride on dry cough in Sjögren's syndrome]. | Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology 20040401 |
| Radiation-induced xerostomia: how dry is your patient? | Clinical journal of oncology nursing 20040201 |
| Ligand-selective signaling and high-content screening for GPCR drugs. | Drug discovery today 20031215 |
| Reduction in distractibility with AF102B and THA in the macaque. | Pharmacology, biochemistry, and behavior 20030901 |
| Age-related decreases in the response of aquaporin-5 to acetylcholine in rat parotid glands. | Journal of dental research 20030601 |
| Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20030401 |
| Effect of SNI-2011 on amylase secretion from parotid tissue in rats and in neuronal nitric oxide synthase knockout mice. | European journal of pharmacology 20030319 |
| Pharmacokinetics and metabolism of the novel muscarinic receptor agonist SNI-2011 in rats and dogs. | Arzneimittel-Forschung 20030101 |
| Pharmacokinetics and metabolism of radiolabelled SNI-2011, a novel muscarinic receptor agonist, in healthy volunteers. Comprehensive understanding of absorption, metabolism and excretion using radiolabelled SNI-2011. | Arzneimittel-Forschung 20030101 |
| Effects of pilocarpine hydrochloride and cevimeline on submandibular/sublingual salivation in rat xerostomia model produced by X-ray irradiation. | Arzneimittel-Forschung 20030101 |
| M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. | Journal of molecular neuroscience : MN 20030101 |
| [Cevimeline hydrochloride hydrate (Saligren capsule 30 mg): a review of its pharmacological profiles and clinical potential in xerostomia]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20021001 |
| Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial. | Archives of internal medicine 20020610 |
| Assessing salivary gland hypofunction--Part two. | Practical procedures & aesthetic dentistry : PPAD 20020401 |
| A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca. | Arthritis and rheumatism 20020301 |
| General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 1st communication: effects on general behavior and central nervous system. | Arzneimittel-Forschung 20020101 |
| General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 2nd communication: effects on somatic nervous system and on autonomic nervous system and smooth muscle. | Arzneimittel-Forschung 20020101 |
| General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 3rd communication: effects on respiratory and cardiovascular systems. | Arzneimittel-Forschung 20020101 |
| General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 4th communication: Effects on gastrointestinal, urinary and reproductive systems and other effects. | Arzneimittel-Forschung 20020101 |
| Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren's syndrome. | Advances in experimental medicine and biology 20020101 |
| Use of muscarinic agonists in the treatment of Sjögren's syndrome. | Clinical immunology (Orlando, Fla.) 20011201 |
| Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011. | Biological & pharmaceutical bulletin 20011101 |
| Salivary enhancement: current status and future therapies. | Journal of dental education 20011001 |
| Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists. | Brain research 20010629 |
| A new medication for treatment of dry mouth in Sjögren's syndrome. | Texas dental journal 20010401 |
| New drug approvals in 2000. | General dentistry 20010101 |
| SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors. | The Journal of pharmacology and experimental therapeutics 19971201 |
| AF102B, a muscarinic M1 receptor agonist, mimics some effects of acetylcholine on neurons of rat hippocampus slices. | European journal of pharmacology 19920910 |
| Central muscarinic activities of an M1-selective agonist: preferential effect on reversal of amnesia. | Brain research 19900115 |
| Amelioration of experimental amnesia (passive avoidance failure) in rodents by the selective M1 agonist AF102B. | Japanese journal of pharmacology 19881201 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.